Clinical trials
Immunogenicity clinical trials
Below are recruiting immunogenicity clinical trials, each written for real people, not researchers. We’re tracking 149 recruiting studies, each written for real people, not researchers, below.
Recruiting studies
- NCT06842173RecruitingPhase 1/Phase 2
Safety testing of new bird flu vaccine (H5N8) in adults
This trial tests a new bird flu (H5N8) vaccine for adults aged 18 and older. It looks at how safe the vaccine is and how well it triggers an immune response. The vaccine is given as a shot and includes an adjuvant to boost protection.
Belo Horizonte, Minas GeraisAges 18 years+ - NCT06843317RecruitingPhase 1
RSV vaccine booster for older adults
This trial tests a booster dose of an experimental RSV vaccine (SCB-1019T) in healthy adults aged 60-85 who have already received the approved RSV vaccine AREXVY. The goal is to see if the booster is safe and boosts your immune system.
Phoenix, ArizonaAges 60–85 - NCT06863142RecruitingPhase 1
Testing a new flu vaccine with or without adjuvant
This study tests a new investigational flu vaccine (FluMos-v2) with or without an adjuvant (ALFQ) to see how safe, tolerable, and effective it is. It may help protect against multiple flu strains.
Bethesda, MarylandAges 18–50 - NCT06874842RecruitingPhase 1
Testing a new shingles vaccine in adults 40 and older
This trial tests a new shingles vaccine (LYB004) in adults 40 and older. It looks at how safe the vaccine is and how well it helps your body build protection against shingles.
MeizhouAges 40 years+ - NCT06885853Recruiting
Long-term immune response to mpox booster in men on PrEP
This study tests how well a booster dose of the MVA-BN mpox vaccine keeps working over time in men who are on or starting PrEP for HIV prevention.
Paris, ParisAges 18 years+ - NCT06928753RecruitingPhase 4
Chikungunya vaccine study in La Réunion
This study is for people who are eligible for the chikungunya vaccine in La Réunion. It looks at how well the vaccine works in real life, if it’s safe, and how your body responds to it.
Saint-DenisAges 18 years+ - NCT06947499RecruitingPhase 2/Phase 3
Testing a 6-in-1 infant vaccine in healthy babies
This study tests a new vaccine that protects babies against 6 diseases (diphtheria, tetanus, whooping cough, hepatitis B, polio, and Hib) in just one shot. It’s for healthy infants starting at 6–8 weeks old as their first series of vaccinations.
Dasmariñas, CaviteAges 1 month–2 months - NCT06960382RecruitingPhase 1/Phase 2
Cat allergy immunotherapy with lymph node injections
This trial tests a new way to treat cat allergies by giving tiny injections directly into a lymph node (a part of your immune system), instead of under the skin. It aims to see if this method is safe and can reduce cat allergy symptoms, even in people with asthma.
ZurichAges 18–65 - NCT06995820RecruitingPhase 1
Safety study of AZD1613 in healthy volunteers
This is a first-in-human trial testing an experimental drug (AZD1613) in healthy volunteers. It helps doctors see if the drug is safe, how it is processed by the body, and how the immune system reacts. The trial is designed for healthy men and women who cannot become pregnant and may require participants to be of Chinese or Japanese descent for certain groups.
Glendale, CaliforniaAges 18–50 - NCT07003984RecruitingPhase 3
Chikungunya vaccine study for children
This study tests a vaccine for chikungunya virus in children aged 1 to 12. It aims to see if the vaccine is safe and helps the body build protection against the virus.
Fountain Valley, CaliforniaAges 1–11 - NCT07025681RecruitingPhase 3
Comparing a new erythropoietin to Eprex for healthy volunteers
This study tests a new erythropoietin (a medicine that helps your body make red blood cells) and compares it to an approved version called Eprex. It is for healthy adults to see how the two medicines work in the body and if they are safe.
Dhaka, Dhaka DivisionAges 18 years+ - NCT07036159RecruitingPhase 2
Malaria vaccine safety study for children ages 5 months to 5 years
This trial tests a new malaria vaccine in healthy children. It aims to see if the vaccine is safe and how well it works in children who have had their regular childhood shots.
KigaliAges 5 months–5 years - NCT07054099RecruitingPhase 3
Testing a chickenpox vaccine for children ages 1 to 12
This study tests a new chickenpox vaccine (MG1111, also called BARYCELA Inj.) in healthy children aged 1 to 12 years. It checks how well the vaccine works and if it is safe, with two doses given over time.
Khon Kaen, Changwat Khon KaenAges 1–12 - NCT07059403RecruitingPhase 1
Safety and dose study of a new hepatitis B vaccine in healthy adults
This study is testing a new hepatitis B vaccine called SN2001 in healthy adults. It will check how safe the vaccine is, what dose works best, and how well it helps your body build protection against hepatitis B.
Herston, QueenslandAges 18–55 - NCT07073547RecruitingPhase 1
Study of AZD0120 for multiple myeloma patients
This trial tests a new drug, AZD0120, in people with multiple myeloma. It aims to find the right dose and see how safe and effective it is. The study includes both newly diagnosed and early relapsed patients.
Phoenix, ArizonaAges 18 years+ - NCT07078994RecruitingPhase 2
Study of a new drug for moderate to severe Crohn's disease
This trial tests a new medicine called BCD-261 for people with moderate to severe Crohn's disease that has not responded well to other treatments. It aims to see if the drug can reduce symptoms and inflammation.
Barnaul, Altayskiy KrayAges 18–75 - NCT07080034RecruitingPhase 2
Testing BCD-261 for moderate to severe ulcerative colitis
This trial tests a new drug called BCD-261 for people with moderate to severe ulcerative colitis that hasn't gotten better with standard treatments. It aims to see if the drug can improve symptoms and how safe it is.
Barnaul, Altayskiy KrayAges 18–75 - NCT07087912RecruitingPhase 4
Dengue vaccine safety in people with autoimmune rheumatic diseases
This study tests the safety and immune response of a dengue vaccine in people aged 12–59 with stable autoimmune rheumatic diseases (like rheumatoid arthritis or lupus) who are on low-dose or no immune-suppressing medications. It also includes healthy volunteers for comparison.
São Paulo, São PauloAges 12–59 - NCT07094711RecruitingPhase 2
BCG vaccine boost for MAC lung disease
This study tests whether a single dose of the BCG vaccine (a live vaccine used for TB) can help the immune system fight MAC lung disease. Participants must not be on MAC treatment now, but may start it during the study if needed.
Charlottesville, VirginiaAges 18 years+ - NCT07103148RecruitingPhase 3
Study of a Yellow Fever Vaccine in Young Children
This trial tests a new yellow fever vaccine in young children. It will see if the vaccine is safe and produces a good immune response, including when given with the MMR vaccine.
San Pedro SulaAges 9 months–5 years - NCT07121413RecruitingPhase 2
Testing SV001 for Idiopathic Pulmonary Fibrosis
This trial tests a new drug called SV001 to see if it is safe and tolerable for people with idiopathic pulmonary fibrosis (IPF). If you have IPF and meet certain health criteria, this study may help find new treatment options.
ChengduAges 40 years+ - NCT07160335RecruitingPhase 1
Testing a potential biosimilar for multiple resected solid tumors
This trial tests whether a new drug, HLX17, works as well as the approved drug Keytruda® in people whose solid tumors (like lung cancer, melanoma, or kidney cancer) have been fully removed by surgery. The goal is to see if the new drug can help prevent the cancer from coming back.
Glendale, CaliforniaAges 18–85 - NCT07176650RecruitingPhase 1
Testing a biosimilar ipilimumab for advanced liver cancer
This trial tests a new version of the immunotherapy drug ipilimumab (called HLX13) against the approved version (YERVOY) for people with advanced liver cancer that cannot be removed by surgery. The goal is to see if the new version works similarly and is as safe.
Glendale, CaliforniaAges 18–65 - NCT07199270RecruitingPhase 1
Safety study of GR2303 in healthy adults
This trial tests a new drug called GR2303 to see if it is safe and how the body processes it. It is for healthy adults who have not used similar drugs before.
Beijing, Beijing MunicipalityAges 18–45
Hear when a new Immunogenicity trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.
Common questions
- Are there clinical trials for immunogenicity?
- Yes. Clin2 currently lists 149 recruiting immunogenicity studies from the U.S. registry, each rewritten for real people, not researchers, so you can see what it’s testing and who it’s for.
- How do I know if I qualify for a immunogenicity trial?
- Each study lists its eligibility criteria — rules about age, diagnosis, and prior treatments. On every Clin2 trial page we explain these in words written for real people and offer a short, optional pre-screen for a fit read. The study team makes the final decision.
- Does it cost anything to join a immunogenicity trial?
- Using Clin2 is always free. Many trials cover the cost of the study treatment and related visits; some reimburse travel. The study team explains exactly what’s covered before you decide.
Related conditions
Clin2 helps you find and understand clinical trials and does not provide medical advice. Study data comes from ClinicalTrials.gov. Talk with your doctor about whether a specific trial is right for you.